MAPT and early-onset autosomal dominant Alzheimer disease: This was the first clinical evaluation of [18F] JNJ-64326067, a high-affinity PET ligand for tau aggregates associated with Alzheimer’s disease, which displays high selectivity over β-amyloid aggregates, absence of affinity for other brain targets especially monoamine oxidase, and suitable metabolic and pharmacokinetic profiles.